Literature DB >> 2138812

[Long-term tolerability of tiopronin (Acadione) in the treatment of rheumatoid arthritis. Apropos of 140 personal cases].

J Sany1, B Combe, D Verdie-Petibon, A Tagemouati, J P Daures.   

Abstract

One hundred and forty patients with classic or definite rheumatoid polyarthritis were treated with N2 mercapto-propionly-glycine: thiopronine (Acadione) at an average dose of 1 g per day over a mean duration of 11.7 months + 10.7 months. The retrospective study of these cases, followed between 1980 and 1988 by the same medical team, permits to evaluate the long-term tolerance of the product. Adverse reaction, always subsiding were observed in 55 p. cent of the patients, requiring discontinuation of the treatment in 40 p. cent of the cases. These side effects occur in 3/4 of the cases, during the first 6 months of the treatment. The intolerance mainly affect skin and mucosae: 46 cases (32.8 p. cent) resulting in 32 instances (22.8 p. cent) discontinuation of the treatment because of stomatitis, pruritus, various types of erythema, pemphigus (1 case). Fourteen patients presented a renal failure (10 p. cent) requiring in 8 instances (5.7 p. cent) discontinuation of the thiopronine because of nephrotic syndrome (3 case) and proteinuria (5 cases). Haematological disorders were observed in 13 instances (9.2 p. cent), justifying, in 10 instances (7.1 p. cent) discontinuation of the treatment because of thrombopenia or leucothrombopenia. The other side effects observed are the following: digestive disorders 15 cases (10.7 p. cent) requiring discontinuation of the treatment in 3 instances (2.1 p. cent), agueusia in 6 instances (4.2 p. cent) requiring discontinuation of the treatment in one case; miscellaneous disorders 13.5 p. cent for which the responsibility of thiopronine is not precisely established (especially hepatic cholostasis, muscle disorders), requiring discontinuation the the treatment in 1.4 p. cent of the cases.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2138812

Source DB:  PubMed          Journal:  Rev Rhum Mal Osteoartic        ISSN: 0035-2659


  5 in total

1.  Nephrotic syndrome occurring during tiopronin treatment for cystinuria.

Authors:  Velibor Tasic; Vladimir J Lozanovski; Nadica Ristoska-Bojkovska; Emilija Sahpazova; Zoran Gucev
Journal:  Eur J Pediatr       Date:  2010-10-06       Impact factor: 3.183

2.  HLA-A33/B44/DR6 is highly related to intrahepatic cholestasis induced by tiopronin.

Authors:  M Kurosaki; H Takagi; M Mori
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.199

3.  Nephrotic syndrome in a patient with cystinuria: Answers.

Authors:  Ozlem Yuksel Aksoy; Nilgun Cakar
Journal:  Pediatr Nephrol       Date:  2019-12-13       Impact factor: 3.714

4.  Protective effects of tiopronin against high fat diet-induced non-alcoholic steatohepatitis in rats.

Authors:  Jian-qing Wang; Yu-hong Zou; Cheng Huang; Chao Lu; Lei Zhang; Yong Jin; Xiong-wen Lü; Li-ping Liu; Jun Li
Journal:  Acta Pharmacol Sin       Date:  2012-04-30       Impact factor: 6.150

5.  The pharmacokinetics of tiopronin and its principal metabolite (2-mercaptopropionic acid) after oral administration to healthy volunteers.

Authors:  B Hercelin; P Leroy; A Nicolas; C Gavriloff; D Chassard; J J Thébault; M T Reveillaud; M F Salles; P Netter
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.